Industry

RICHARDSON, Texas–(BUSINESS WIRE)–#MLR–MedeAnalytics, the healthcare performance improvement company, today announced its participation in a series of leading payer-focused industry events, including a Becker’s Payer Issues webinar, the 2026 Becker’s Payer Issues Spring Roundtable, and 2026 OpsIgnite. These engagements underscore MedeAnalytics’ commitment to helping health plans move beyond fragmented data and siloed analytics to drive measurable … [Read more…]

FARMINGDALE, N.Y.–(BUSINESS WIRE)–SkyHope, a nonprofit organization providing free air transportation to patients in need of specialized medical care, is pleased to announce the appointment of Bradley D. Mottier to its Board of Directors. Mottier brings more than 40 years of leadership experience in aerospace and aviation. He retired in 2023 as Senior Vice President & … [Read more…]

Healthcare clinics across the US are using Insight Health’s voice-first clinical agents to save hundreds of thousands of hours and millions of dollars in annual administrative costs. NEW YORK–(BUSINESS WIRE)–Insight Health, the clinical agent platform for healthcare, today announced an $11 million Series A funding round led by Standard Capital, with participation from Pear VC, … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#Biotech–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference: Kempen Life Sciences Conference Dates: April 15 –16, 2026 Location: Amsterdam, Netherlands … [Read more…]

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options … [Read more…]

Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered cellular medicines VANCOUVER, British Columbia–(BUSINESS WIRE)–Aspect Biosystems, a biotechnology company pioneering a novel category of regenerative medicine, today announced that it has received a $79 million investment from the Government of Canada. The investment will support a $280 million, multi-year … [Read more…]

SEATTLE–(BUSINESS WIRE)–#AI–FINAO SPV Inc. (a venture between FINAO® and Rubix Network) has announced it is working with the YMCA to build The YMCA Wellness Café™, a HIPAA compliant wellness chain that will serve the global YMCA network. YMCA in collaboration with FINAO (A wellness solution platform) and Rubix (Blockchain co.) has developed The YMCA Wellness … [Read more…]

WELL Health and AliveCor have partnered to bring rapid, cardiologist-reviewed ECG services to patients across Canada through the Kardia platform. Under this partnership, WELL Health’s Canadian-registered cardiologists are integrated directly into AliveCor’s AI-powered Kardia platform, providing paid clinical interpretation services that give patients expert, physician-validated insight into their heart data, all from home. Cardiologist-reviewed ECG … [Read more…]

 Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong Commercial Platform in Rare Disease to Support Future Launches OSAKA, Japan–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, … [Read more…]

Designation granted by FDA recognizes the potential of plixorafenib, a novel, investigational paradox breaker and BRAF inhibitor, to provide substantial improvement over available therapies First Breakthrough Therapy Designation granted to a targeted therapy for High-Grade Glioma (HGG) is in addition to Fast Track Designation and Orphan Drug Designation plixorafenib already received encompassing CNS tumors Topline … [Read more…]